Cell line · CVCL_1579
Papers85
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 85
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Differential Sensitivity to xCT-inhibition by ME1 expression. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| SCLC humanized mice identify T cell infiltration phenotypes in response to combination immune-radiation therapies. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Evaluation of Tissue from Patients with Prostate Cancer Identifies B7-H3 as an Androgen-Regulated, Broadly Expressed, Combinatorial Therapeutic Target. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| c-JUN enhances CRISPR knockin anti-B7-H3 CAR T cell function in small cell lung cancer and thoracic SMARCA4-deficient undifferentiated tumors. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| KDM7B-mediated demethylation of RNF113A regulates small cell lung cancer sensitivity to alkylation damage. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| In Vitro Anticancer Activity of Phytol on Human Non-Small Cell Lung Cancer A549 Cells. | Integr Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The Potential of Single-Transcription Factor Gene Expression by RT-qPCR for Subtyping Small Cell Lung Cancer. | Int J Mol Sci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Jumonji histone demethylases are therapeutic targets in small cell lung cancer. | Oncogene | 2024 | Cellosaurus cites it | PubMed | |
| Teriflunomide/leflunomide synergize with chemotherapeutics by decreasing mitochondrial fragmentation via DRP1 in SCLC. | iScience | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Subtype-selective prenylated isoflavonoids disrupt regulatory drivers of MYCN-amplified cancers. | Cell Chem Biol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1. | Cell Rep Med | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Hematopoietic transcription factor GFI1 promotes anchorage independence by sustaining ERK activity in cancer cells. | J Clin Invest | 2022 | Its Methods give the RRID and name the line | PubMed | |
| SMYD3 Impedes Small Cell Lung Cancer Sensitivity to Alkylation Damage through RNF113A Methylation-Phosphorylation Cross-talk. | Cancer Discov | 2022 | Its Methods give the RRID and name the line | PubMed | |
| WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. | Cell Rep | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer. | Cancer | 2022 | Its Methods give the RRID and name the line | PubMed | |
| MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer. | iScience | 2021 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1579/papers